Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Oruka Therapeutics (Nasdaq: ORKA), a biotechnology company focused on developing novel biologics for chronic skin diseases treatment, has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI). The inclusion will be effective before market open on December 23rd, 2024. This addition reflects Oruka's meeting of specific eligibility criteria, including minimum market capitalization requirements, average daily trading volume thresholds, and public company seasoning period. The NBI tracks performance of biotechnology and pharmaceutical companies listed on Nasdaq, using a modified capitalization-weighted methodology with annual evaluation in December.
Oruka Therapeutics (Nasdaq: ORKA), un'azienda biotecnologica focalizzata sullo sviluppo di nuovi biologici per il trattamento delle malattie cutanee croniche, ha annunciato la sua prossima inclusione nell'Indice Biotecnologico Nasdaq (NBI). L'inclusione sarà effettiva prima dell'apertura del mercato il 23 dicembre 2024. Questa aggiunta riflette il soddisfacimento da parte di Oruka di specifici requisiti di idoneità, inclusi i requisiti minimi di capitalizzazione di mercato, le soglie medie del volume di scambi giornalieri e il periodo di assestamento della società pubblica. L'NBI monitora le performance delle aziende biotecnologiche e farmaceutiche quotate su Nasdaq, utilizzando una metodologia modificata ponderata per la capitalizzazione con valutazione annuale a dicembre.
Oruka Therapeutics (Nasdaq: ORKA), una empresa biotecnológica centrada en el desarrollo de nuevos biológicos para el tratamiento de enfermedades cutáneas crónicas, ha anunciado su próxima inclusión en el Índice de Biotecnología Nasdaq (NBI). La inclusión será efectiva antes de la apertura del mercado el 23 de diciembre de 2024. Esta adición refleja que Oruka ha cumplido con criterios específicos de elegibilidad, incluidas las requisitos mínimos de capitalización de mercado, los umbrales promedio de volumen de negociación diario y el período de maduración de la empresa pública. El NBI realiza un seguimiento del rendimiento de las empresas biotecnológicas y farmacéuticas que cotizan en Nasdaq, utilizando una metodología ponderada por capitalización modificada con evaluación anual en diciembre.
오루카 테라퓨틱스 (Nasdaq: ORKA), 만성 피부 질환 치료를 위한 새로운 생물학적 제제를 개발하는 데 중점을 둔 생명공학 회사가 나스닥 생명공학 지수(NBI)에 포함될 예정이라고 발표했습니다. 이 포함은 2024년 12월 23일 시장 개장 전에 유효할 것입니다. 이번 추가는 오루카가 최소 시가총액 요구 사항, 평균 일일 거래량 기준, 공기업 소요 기간 등의 특정 자격 요건을 충족했음을 반영합니다. NBI는 나스닥에 상장된 생명공학 및 제약 회사의 성과를 추적하며, 연말에 연간 평가를 기준으로 수정된 시가 총액 가중 방법론을 사용합니다.
Oruka Therapeutics (Nasdaq: ORKA), une entreprise de biotechnologie axée sur le développement de nouveaux biologiques pour le traitement des maladies cutanées chroniques, a annoncé son incorporation prochaine dans le Nasdaq Biotechnology Index (NBI). Cette inclusion sera effective avant l'ouverture du marché le 23 décembre 2024. Ce ajout reflète le respect par Oruka de critères d'éligibilité spécifiques, y compris les exigences minimales en matière de capitalisation boursière, les seuils moyens de volume de négociation quotidien et la période de disponibilité de l'entreprise publique. Le NBI suit la performance des entreprises biotechnologiques et pharmaceutiques cotées sur Nasdaq, en utilisant une méthodologie modifiée pondérée par la capitalisation avec une évaluation annuelle en décembre.
Oruka Therapeutics (Nasdaq: ORKA), ein Biotechnologieunternehmen, das sich auf die Entwicklung neuer Biologika zur Behandlung chronischer Hauterkrankungen konzentriert, hat seine bevorstehende Aufnahme in den Nasdaq Biotechnology Index (NBI) angekündigt. Die Aufnahme wird vor der Markteröffnung am 23. Dezember 2024 wirksam. Diese Ergänzung spiegelt wider, dass Oruka spezifische Zulassungskriterien erfüllt hat, einschließlich der Mindestanforderungen an die Marktkapitalisierung, der durchschnittlichen täglichen Handelsvolumen sowie der Frist für öffentliche Unternehmen. Der NBI verfolgt die Leistung von Biotechnologie- und Pharmaunternehmen, die an der Nasdaq gelistet sind, und verwendet eine modifizierte kapitalisierungsgewichtete Methodik mit jährlicher Bewertung im Dezember.
- Addition to Nasdaq Biotechnology Index (NBI) increases visibility and potential institutional investment
- Company meets NBI's strict eligibility requirements for market cap, trading volume, and listing standards
- None.
Insights
The addition to the Nasdaq Biotechnology Index represents a significant milestone for Oruka Therapeutics, potentially increasing its visibility among institutional investors and index funds that track the NBI. With a market cap of
However, investors should note that while index inclusion is positive for visibility, the fundamental value proposition and clinical development progress remain the key drivers for long-term performance. The NBI addition validates Oruka's market presence but doesn't directly impact its drug development timeline or probability of success in treating chronic skin diseases.
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka’s addition will become effective prior to market open on Monday, December 23rd, 2024.
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
FAQ
When will Oruka Therapeutics (ORKA) be added to the Nasdaq Biotechnology Index?
What requirements did Oruka Therapeutics (ORKA) meet to join the Nasdaq Biotechnology Index?
What is Oruka Therapeutics' (ORKA) main business focus?
How often is the Nasdaq Biotechnology Index (NBI) that ORKA is joining evaluated?
